OptiBiotix Health (LON:OPTI) Insider David Blain Buys 158,965 Shares

OptiBiotix Health Plc (LON:OPTIGet Free Report) insider David Blain purchased 158,965 shares of the stock in a transaction dated Thursday, May 28th. The shares were purchased at an average price of GBX 6 per share, with a total value of £9,537.90.

OptiBiotix Health Stock Performance

OptiBiotix Health stock opened at GBX 6.05 on Friday. The company has a 50-day simple moving average of GBX 5.31 and a 200-day simple moving average of GBX 6.35. The firm has a market capitalization of £6.25 million, a P/E ratio of -201.67 and a beta of 1.71. OptiBiotix Health Plc has a one year low of GBX 4.50 and a one year high of GBX 15.

OptiBiotix Health (LON:OPTIGet Free Report) last released its quarterly earnings results on Thursday, May 28th. The company reported GBX (3.84) EPS for the quarter. The firm had revenue of GBX 117 million for the quarter. OptiBiotix Health had a negative return on equity of 2.27% and a negative net margin of 16.59%.

About OptiBiotix Health

(Get Free Report)

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome – the collective genome of the microbes in the body – in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products.

Read More

Receive News & Ratings for OptiBiotix Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiBiotix Health and related companies with MarketBeat.com's FREE daily email newsletter.